Probiotics Administration Via Colonoscopic Spray and Oral Administration in CDAD Patients (CDAD)
Diarrhea Infectious
About this trial
This is an interventional treatment trial for Diarrhea Infectious focused on measuring Clostridioides difficile colitis
Eligibility Criteria
Inclusion Criteria: patients aged ≥ 20 years who are diagnosed with C. difficile colitis Exclusion Criteria: patients are diagnosed with colitis because of other etiologies, such as intestinal Behçet's disease, amoeba or parasitic colitis, Salmonella colitis, lymphoma, E. coli colitis, cytomegalovirus colitis, ischemic colitis, sigmoid-colon cancer, inflammatory bowel diseases (ulcerative colitis or Crohn's disease), solitary rectal ulcer syndrome, radiation colitis patients who have contraindications for colonoscopy, including declining or refusal to cooperate unstable vital signs a diagnosis or highly suspicion of colon rupture a high-risk situation for colon perforation such as acute diverticulitis toxic megacolon, etc. acute myocardial infarct
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
probiotics-spray (PS) group
probiotics-oral (PO) group
In the PS group, the colonoscopic prescription of 10 grams of probiotics powder is performed once on one of the first three days (D0-D3).
In the PO group, we will prescribe oral probiotics 2 capsules once per day for 5 days (a total of 10 grams) as adjunctive treatment during the first five days (D0-D4).